Insmed Incorporated

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 21/06/2025 am IST			5-day change	1st Jan Change
102.68 ^USD	+3.24%		+4.00%	+48.73%

13/06	Insmed Insider Sold Shares Worth $5,148,024, According to a Recent SEC Filing	MT
12/06	Insmed Prices $750 Million Common Stock Offering	MT

Insmed Says Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints

Published on 10/06/2025 at 17:36

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Insmed Incorporated

Insmed Insider Sold Shares Worth $5,148,024, According to a Recent SEC Filing	13/06	MT
Insmed Prices $750 Million Common Stock Offering	12/06	MT
Insmed Announces Pricing Of $750 Million Public Offering Of Common Stock At $96 Per Share	12/06	RE
Insmed Plans $650 Million Public Offering	12/06	MT
Insmed Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09:20 AM	12/06
BofA Securities Raises Insmed Price Target to $109 From $94, Maintains Buy Rating	11/06	MT
BofA Securities Raises Insmed Price Target to $109 From $94, Maintains Buy Rating	11/06	MT
CPI Relief Sparks Wall Street Optimism	11/06
RBC Raises Price Target on Insmed to $106 From $99, Keeps Outperform Rating	11/06	MT
Morgan Stanley Raises Price Target on Insmed to $102 From $90, Keeps Overweight Rating	11/06	MT
Mizuho Raises Price Target on Insmed to $110 From $96, Keeps Outperform Rating	11/06	MT
Analyst recommendations: Arista Networks, Etsy, Micron Technology, Docusign, Gitlab…	11/06
Equity Markets Close Higher After US-China Trade Talks Stretch Over Second Day	11/06	MT
Sector Update: Health Care Stocks Rise Late Afternoon	11/06	MT
Sector Update: Health Care Stocks Higher Tuesday Afternoon	10/06	MT
Insmed Incorporated - Special Call	10/06
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	10/06	MT
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	10/06	RE
Wall Street mixed as US-China trade talks grab focus	10/06	RE
Insmed Incorporated Announces Positive Topline Results from Phase 2B Study of Treprostinil Palmitil Inhalation Powder as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension	10/06	CI
Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints	10/06	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	10/06	MT
Wall St set to open slightly higher as US-China trade talks grab focus	10/06	RE
Sector Update: Health Care	10/06	MT
Insmed Shares Rise on Positive Results From Study of Treatment for High Blood Pressure in Lungs	10/06	DJ

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,271

Sector

Biotechnology & Medical Research

Calendar

31/07 - Q2 2025 Earnings Release (Projected)

More about the company